ARCHIVES

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 1 | January 31, 2014

Download PDF Visit The Full Archive

Related Articles

Top Officials Resign From San Antonio’s Institute for Drug Development.

January 26, 2007

DCPC Bard Approves Concepts For New Grant Programs

November 13, 1992

FDA to Move Away From Central Radiology To Investigator Review In PFS Endpoint Trials

July 27, 2012

Drug Effectiveness Weakens After Three Years, Study Says

May 27, 2011

Senate Committee Blocks Effort To Overturn Organ Systems Changes

December 10, 1982

Cancer Act 25th Year: cancer Mortality Rate Began decline In 1990s, NCI, ACS Studies Find

November 22, 1996